Revvity (RVTY) Reports Financial Earnings Results For The First Quarter Of 2025

Revvity, Inc. (RVTY) today announced its financial results for the recent quarter, showcasing a mixed performance. The company reported earnings per share of $1.01, surpassing the estimated $0.95 and marking a positive earnings surprise. However, Revvity faced a significant challenge on the revenue front, posting a quarterly revenue of -$10.08 million, which fell short of the expected $661 million. This revenue miss highlights the hurdles the company is navigating in the current economic landscape.

Key Highlights:

• Revvity reported a revenue of $665 million for Q1 2025, marking a 2% reported growth and 4% organic growth.
• GAAP earnings per share (EPS) were $0.35, with adjusted EPS from continuing operations at $1.01.
• The company reaffirmed its full-year 2025 guidance for organic growth and adjusted EPS.
• Life Sciences segment saw a 1% revenue increase to $340 million, with a 2% organic growth.
• Diagnostics segment revenue increased by 3% to $324 million, with a 5% organic growth.
• Full-year 2025 revenue guidance was raised to $2.83-$2.87 billion, with an organic growth expectation of 3-5%.
• CEO Prahlad Singh highlighted strong execution and adaptability to the evolving macroeconomic environment as key factors for the company’s performance.
• Revvity’s Board of Directors declared a regular quarterly dividend of $0.07 per share of common stock, payable on August 8, 2025.
• The Massachusetts Superior Court ruled in favor of Revvity, granting a permanent injunction to enforce its agreements with Cloud Software Group regarding the Spotfire® software.

Summary:

Revvity, Inc. has reported a strong financial performance for the first quarter of 2025, with a revenue of $665 million, reflecting a 2% increase from the previous year and a 4% organic growth. The company achieved a GAAP EPS of $0.35 and an adjusted EPS from continuing operations of $1.01. The Life Sciences segment reported a 1% revenue increase to $340 million, while the Diagnostics segment saw a 3% increase to $324 million, with both segments experiencing organic growth. CEO Prahlad Singh attributed the company’s success to strong execution and the unique nature of its business operations, which have allowed Revvity to exceed expectations despite a dynamic environment. The company has raised its full-year 2025 revenue guidance to a range of $2.83-$2.87 billion, reflecting recent changes in foreign currency exchange rates, and reaffirmed its organic growth guidance of 3-5% and adjusted EPS guidance of $4.90-$5.00.

Looking ahead, Revvity remains focused on its strategic initiatives to drive sustainable growth and enhance shareholder value. The company announced a regular quarterly dividend of $0.07 per share, payable on August 8, 2025, demonstrating its commitment to returning value to shareholders. Additionally, Revvity secured a legal victory with the Massachusetts Superior Court ruling in its favor, granting a permanent injunction to enforce its agreements with Cloud Software Group concerning the Spotfire® software. This ruling ensures uninterrupted access to the software and support for Revvity and its customers, thereby protecting its operational capabilities and customer service commitments. The management’s confidence in achieving its targets is reflected in their commitment to maintaining robust operational performance and financial discipline.

Revvity, Inc. (RVTY) has experienced a tumultuous period in the stock market, with its price showing a significant decline over the past few months. Over the last three months, the stock has plummeted by 23.38%, and it has seen a 12.12% drop in just the past month. Despite a slight recovery of 2.69% in the last week, the overall trend remains negative, with a 7.40% decrease over the past year. This downward trajectory in stock price is mirrored by the company’s fundamental metrics, which paint a challenging picture. The price-to-earnings ratio stands at a high 39.26, suggesting that the stock might be overvalued given its current earnings. Additionally, Revvity’s revenue and free cash flow have both contracted over the past two years, with compound annual growth rates of -16.40% and -4.03%, respectively. The company’s return on invested capital is a modest 3.65%, and while the net profit margin is a decent 10.52%, the negative growth in earnings per share (-1.68% CAGR) indicates potential struggles in maintaining profitability. These metrics suggest that Revvity may need to address its operational efficiencies and growth strategies to regain investor confidence.

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.